GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (STU:8ZD) » Definitions » Total Receivables

Abbisko Cayman (STU:8ZD) Total Receivables : €6.44 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Abbisko Cayman Total Receivables?

Abbisko Cayman's Total Receivables for the quarter that ended in Jun. 2024 was €6.44 Mil.


Abbisko Cayman Total Receivables Historical Data

The historical data trend for Abbisko Cayman's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Total Receivables Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Receivables
0.22 1.15 3.68 5.94 6.13

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Receivables Get a 7-Day Free Trial Premium Member Only - 5.94 5.82 6.13 6.44

Abbisko Cayman Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Abbisko Cayman Total Receivables Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbisko Cayman Business Description

Traded in Other Exchanges
Address
Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is a investment holding company it operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.

Abbisko Cayman Headlines

No Headlines